Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial-Reference-Cited by-同舟云学术

Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial

Published:2017-01 Issue:1 Volume:23 Page:176-179
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Woo Janghee,Deeg H. Joachim,Storer Barry,Yeung Cecilia^ORCID,Fang Min,Mielcarek Marco,Scott Bart L.

Funder

NIH

Histogenetics

Celgene

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference9 articles.

1. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission;Walter;Leukemia,2010

2. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning;Kahl;Blood,2007

3. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation;Mielcarek;Biol Blood Marrow Transplant,2007

4. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study;Bejanyan;Biol Blood Marrow Transplant,2015

5. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study;de Lima;Cancer,2010

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation;Journal of Clinical Oncology;2024-04-20

2. Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome Patients;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

3. Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation;International Journal of Molecular Sciences;2023-10-09

4. Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression;Leukemia & Lymphoma;2023-08-12

5. Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report;eJHaem;2022-11-16